- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04062448
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
March 28, 2024 updated by: Janssen Pharmaceutical K.K.
Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Combination With Rituximab, in Japanese Patients With Waldenstrom's Macroglobulinemia (WM)
The purpose of this study is to evaluate overall response rate (ORR) by Independent Review Committee (IRC) assessment, when combined with rituximab in Japanese participants with treatment naïve or relapsed/refractory Waldenstrom's Macroglobulinemia (WM).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chiba, Japan, 296-8602
- Kameda General Hospital
-
Chuo-Ku, Japan, 104-0045
- National Cancer Center Hospital
-
Kumamoto City, Japan, 860 0008
- National Hospital Organization Kumamoto Medical Center
-
Matsuyama-City, Japan, 790-8524
- Matsuyama Red Cross Hospital
-
Nagoya-City, Japan, 467-8602
- Nagoya City University Hospital
-
Osaka, Japan, 545 8586
- Osaka Metropolitan University Hospital
-
Suita-City, Japan, 565-0871
- Osaka University Hospital
-
Tachikawa, Japan, 190-0014
- National Hospital Organization Disaster Medical Center
-
Tsukuba-City, Japan, 305-8576
- University of Tsukuba Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia (WM) in accordance with the consensus panel of the second International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
- Japanese participants with treatment naïve or relapsed/refractory WM
- Measurable disease defined as serum monoclonal immunoglobulin M (IgM) greater than (>) 0.5 gram per deciliter (g/dL)
- Symptomatic disease, requiring treatment
- Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (<=) 2
- Hematology and biochemical values within protocol-defined limits
- Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective methods of contraception while taking study drug. Women of childbearing potential must be practicing a highly effective, preferably user independent method of birth control during treatment with any drug in this study and for up to 12 months after the last dose of rituximab, 1 month after last dose of ibrutinib. Male participants must use an effective barrier method of contraception during the study and after receiving the last dose of ibrutinib, and for up to 12 months after last dose of rituximab if sexually active with a female of childbearing potential
- Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study. Participants must be willing and able to adhere to the prohibitions and restrictions specified in this protocol
- Must be willing and able to adhere to the lifestyle restrictions specified in this protocol
Exclusion Criteria:
- Involvement of the central nervous system by WM
- Prior exposure to ibrutinib or other Bruton's Tyrosine Kinase (BTK) inhibitors
- Rituximab treatment within the last 12 months before the first dose of study intervention
- Received any WM-related therapy <=30 days prior to first administration of study treatment
- Plasmapheresis less than (<) 35 days prior to the initiation of study drug, except when at least one serum IgM central assessment was performed during the screening period and was >35 days from the most recent plasmapheresis procedure
- History of other malignancies
- Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
- Infection requiring systemic treatment that was completed <=14 days before the first dose of study drug
- Currently active, clinically significant Child-Pugh Class B or C hepatic impairment
- Inability or difficulty swallowing capsules, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function
- Stroke or intracranial hemorrhage within 12 months prior to enrollment
- Currently active, clinically significant cardiovascular disease
- Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
- Infection with human immunodeficiency virus (HIV) or active infection with hepatitis B or hepatitis C virus
- Major surgery within 4 weeks of first dose of study drug
- Lactating or pregnant
- Male participants who plan to father a child while enrolled in this study or within 3 months after the last dose of ibrutinib, and within 12 months after last dose of rituximab
- Any contraindication to ibrutinib or rituximab including hypersensitivity to the active substance or to any of the excipients of ibrutinib or rituximab per local prescribing information
- Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before the planned first dose of study intervention or is currently enrolled in an investigational study
- Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg [for example], compromise the wellbeing) or that could prevent, limit, or confound the protocol-specified assessments
- Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibrutinib + Rituximab
Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.
|
Ibrutinib 420 mg will be administered orally.
Other Names:
Rituximab 375 mg/m^2 will be administered intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR) According to the Modified Sixth International Workshop on Waldenstrom's Macroglobulinemia (IWWM) Criteria
Time Frame: Up to 1 year 11 months
|
ORR is defined as the percentage of participants achieving a best overall response of confirmed complete response (CR), very good partial response (VGPR) or partial response (PR) according to the modified sixth IWWM criteria (National Comprehensive Cancer Network [NCCN] version 2, 2019), as assessed by the Independent Review Committee (IRC).
CR: Immunoglobulin M (IgM) in normal range, disappearance of monoclonal protein by immunofixation, no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly (if present at baseline) along with no signs or symptoms attributable to Waldenstrom's Macroglobulinemia (WM); VGPR and PR: greater than or equal to (>=) 90 percent (%) (for VGPR) and >=50% (for PR) reduction of serum IgM, decrease in adenopathy/organomegaly (if present at baseline) on physical examination or computerized tomography (CT) scan, no new symptoms or signs of active disease.
|
Up to 1 year 11 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Concentrations of Ibrutinib
Time Frame: Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose
|
Plasma concentrations of ibrutinib were reported.
|
Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose
|
Progression Free Survival (PFS) Assessed by Independent Review Committee
Time Frame: From the date of initial dose up to 3 years and 5 months
|
PFS was defined as duration from the date of initial dose of ibrutinib to the date of first documented evidence of disease progression or death, whichever occurred first regardless of the use of subsequent antineoplastic therapy prior to documented disease progression or death.
Kaplan-Meier method was used for the analysis.
|
From the date of initial dose up to 3 years and 5 months
|
Plasma Concentrations of Metabolite PCI-45227
Time Frame: Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose
|
Plasma concentrations of metabolite PCI-45227 were reported.
|
Day 1 of Week 4: Predose, 1 hour, 2 hours, 4 hours, and 6 hours postdose
|
Number of Participants With Myeloid Differentiation Primary Response Gene 88 (MYD88) Biomarker Mutation
Time Frame: Day 1 of Week 1
|
Number of participants with MYD88 biomarker mutations were reported.
MYD88 was assessed using next generation sequencing to detect the somatic mutations in the bone marrow aspiration samples collected during the study.
|
Day 1 of Week 1
|
Number of Participants With C-X-C Chemokine Receptor Type 4 (CXCR-4) Biomarker Mutations
Time Frame: Day 1 of Week 1
|
Number of participants with CXCR-4 biomarker mutations were reported.
CXCR-4 was assessed using next generation sequencing to detect the somatic mutations in the bone marrow aspiration samples collected during the study.
|
Day 1 of Week 1
|
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)
Time Frame: From first dose of study drug up to 30 days post last dose of study drug (that is, up to 40.6 months)
|
An adverse event was defined as any untoward medical event that occurred in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
TEAEs were defined as any AE that occurred at or after the initial administration of study intervention through the day of last dose plus 30 days.
|
From first dose of study drug up to 30 days post last dose of study drug (that is, up to 40.6 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Janssen Pharmaceutical K.K., Japan Clinical Trial, Janssen Pharmaceutical K.K.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 25, 2019
Primary Completion (Actual)
August 24, 2021
Study Completion (Actual)
March 2, 2023
Study Registration Dates
First Submitted
August 19, 2019
First Submitted That Met QC Criteria
August 19, 2019
First Posted (Actual)
August 20, 2019
Study Record Updates
Last Update Posted (Actual)
April 1, 2024
Last Update Submitted That Met QC Criteria
March 28, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Waldenstrom Macroglobulinemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Rituximab
- Ibrutinib
Other Study ID Numbers
- CR108666
- 54179060WAL2002 (Other Identifier: Janssen Pharmaceutical K.K., Japan)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical
trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Waldenstrom Macroglobulinemia
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingWaldenstrom Macroglobulinemia | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedRecurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
BeiGeneRecruitingWaldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia RefractoryUnited States, Australia, France, China, Spain, United Kingdom
-
Kosin University Gospel HospitalRecruitingWaldenström's MacroglobulinemiaKorea, Republic of
-
BeiGeneCompletedWaldenström's MacroglobulinemiaUnited States, Spain, Australia, France, United Kingdom, Germany, Netherlands, Czechia, Italy, Poland, Belgium, Greece, Sweden
-
Dana-Farber Cancer InstituteBristol-Myers SquibbActive, not recruitingWaldenstrom's MacroglobulinemiaUnited States
-
Dana-Farber Cancer InstituteJanssen, LPCompletedWaldenström MacroglobulinemiaUnited States
-
Central Hospital, Nancy, FranceCompletedWaldenström MacroglobulinemiaFrance
-
Fondazione Italiana Linfomi ONLUSCompletedWaldenstrom's MacroglobulinemiaItaly
Clinical Trials on Ibrutinib
-
Christian BuskeAmgen; Janssen, LPRecruitingWaldenstrom MacroglobulinemiaAustria, Germany, Greece
-
TG Therapeutics, Inc.CompletedMantle Cell Lymphoma | Chronic Lymphocytic LeukemiaUnited States
-
Johnson & Johnson Private LimitedCompletedLymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-CellIndia
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Oncternal Therapeutics, IncUniversity of California, San Diego; Pharmacyclics LLC.; California Institute...Active, not recruitingMantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
The Lymphoma Academic Research OrganisationJanssen Pharmaceutica N.V., BelgiumTerminatedB-cell LymphomaFrance, Belgium
-
Pharmacyclics Switzerland GmbHJanssen Biotech, Inc., including Johnson & JohnsonEnrolling by invitationLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host DiseaseUnited States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
-
Janssen-Cilag Ltd.CompletedLymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-CellFrance
-
The Lymphoma Academic Research OrganisationCompletedIntraocular Lymphoma | Primary Central Nervous LymphomaFrance